B. Paul Morgan

Researcher Next ID · RN-032879

Researcher · Immunology and Microbiology

London, Canada

Accepting doctoral researchersFunding unknown

Research interests

Immunology and Microbiology

Medicine

Neuroscience

Complement system in diseases

Monoclonal and Polyclonal Antibodies Research

Neuroinflammation and Neurodegeneration Mechanisms

Erythrocyte Function and Pathophysiology

Blood groups and transfusion

Research priorities for the COVID‐19 pandemic and beyond: A call to action for psychological science
British Journal of Psychology · 2020 · https://doi.org/10.1111/bjop.12468
Inflammatory biomarkers in Alzheimer's disease plasma
Alzheimer s & Dementia · 2019 · https://doi.org/10.1016/j.jalz.2019.03.007
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Kidney International · 2016 · https://doi.org/10.1016/j.kint.2016.10.005
C3 glomerulopathy: consensus report
Kidney International · 2013 · https://doi.org/10.1038/ki.2013.377
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Science · 2011 · https://doi.org/10.1126/science.1200113
IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†
Brain · 2008 · https://doi.org/10.1093/brain/awn092
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
PubMed · 1990

No projects listed.